NxStage Medical Inc. (NASDAQ:NXTM) SVP Matthew W. Towse sold 4,300 shares of the company’s stock in a transaction on Monday, November 21st. The stock was sold at an average price of $26.23, for a total value of $112,789.00. Following the completion of the sale, the senior vice president now owns 23,041 shares of the company’s stock, valued at $604,365.43. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of NxStage Medical Inc. (NASDAQ:NXTM) traded down 3.3291% on Tuesday, reaching $24.9701. The company had a trading volume of 55,182 shares. NxStage Medical Inc. has a 52 week low of $13.49 and a 52 week high of $26.83. The company’s market capitalization is $1.62 billion. The company has a 50 day moving average of $24.32 and a 200-day moving average of $22.44.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Hedge funds have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC increased its stake in NxStage Medical by 1,459.3% in the second quarter. Acrospire Investment Management LLC now owns 4,678 shares of the medical device company’s stock worth $101,000 after buying an additional 4,378 shares during the last quarter. Pacad Investment Ltd. purchased a new stake in NxStage Medical during the second quarter worth about $111,000. BNP Paribas Arbitrage SA increased its stake in NxStage Medical by 57.5% in the second quarter. BNP Paribas Arbitrage SA now owns 5,548 shares of the medical device company’s stock worth $120,000 after buying an additional 2,026 shares during the last quarter. BlackRock Inc. increased its stake in NxStage Medical by 50.6% in the second quarter. BlackRock Inc. now owns 6,299 shares of the medical device company’s stock worth $136,000 after buying an additional 2,116 shares during the last quarter. Finally, Cutler Group LP increased its stake in NxStage Medical by 28.3% in the second quarter. Cutler Group LP now owns 7,168 shares of the medical device company’s stock worth $155,000 after buying an additional 1,583 shares during the last quarter. 98.86% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages recently weighed in on NXTM. Northland Securities set a $25.00 price objective on NxStage Medical and gave the stock a “buy” rating in a research note on Thursday, September 15th. BTIG Research restated a “buy” rating and set a $29.00 price objective on shares of NxStage Medical in a research note on Sunday, August 7th. Jefferies Group upped their price objective on NxStage Medical from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday, August 5th. Zacks Investment Research cut NxStage Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, August 10th. Finally, Canaccord Genuity upped their price objective on NxStage Medical from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 2nd. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the stock. NxStage Medical has a consensus rating of “Buy” and a consensus target price of $25.67.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.

5 Day Chart for NASDAQ:NXTM

Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.